Table 3.
Correlation between CTAs expression at mRNA level and clinicopathological features
| Variables |
MAGEA1
|
MAGEA10
|
MAGEB2
|
KK-LC-1
|
CTAG1A/B
|
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| High
|
Low
|
P-valuea | High
|
Low
|
P-value | High
|
Low
|
P-value | High
|
Low
|
P-value | High
|
Low
|
P-value | |
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | ||||||
| Gender | 0.289 | 0.689 | 1.000 | 0.296 | 1.000 | ||||||||||
| Male | 9 (34.6) | 17 (65.4) | 21 (80.8) | 5 (19.2) | 20 (76.9) | 6 (23.1) | 8 (30.8) | 18 (69.2) | 18 (69.2) | 8 (30.8) | |||||
| Female | 7 (58.3) | 5 (41.7) | 9 (75.0) | 3 (25.0) | 9 (75.0) | 3 (25.0) | 6 (50.0) | 6 (50.0) | 8 (66.7) | 4 (33.3) | |||||
| Age (years) | 0.187 | 0.216 | 0.115 | 0.298 | 0.027 | ||||||||||
| <60 | 8 (33.3) | 16 (66.7) | 17 (70.8) | 7 (29.2) | 16 (66.7) | 8 (33.3) | 7 (29.20) | 17 (70.8) | 13 (54.2) | 11 (45.8) | |||||
| ≥60 | 8 (57.1) | 6 (42.9) | 13 (92.9) | 1 (7.1) | 13 (92.9) | 1 (7.1) | 7 (50.0) | 7 (50.0) | 13 (92.9) | 1 (7.1) | |||||
| Smoking | 0.713 | 0.411 | 0.673 | 1.000 | 0.694 | ||||||||||
| Never | 5 (50.0) | 5 (50.0) | 7 (70.0) | 3 (30.0) | 7 (70.0) | 3 (30.0) | 4 (40.0) | 6 (60.0) | 6 (60.0) | 4 (40.0) | |||||
| Ever | 11 (39.3) | 17 (60.7) | 23 (82.1) | 5 (17.9) | 22 (78.6) | 6 (21.4) | 10 (35.7) | 18 (64.3) | 20 (71.4) | 8 (28.6) | |||||
| T stage | 1.000 | 1.000 | 0.613 | 0.383 | 0.357 | ||||||||||
| T1–2 | 14 (43.8) | 18 (56.2) | 25 (78.1) | 7 (21.9) | 25 (78.1) | 7 (21.9) | 13 (40.6) | 19 (59.4) | 23 (71.9) | 9 (28.1) | |||||
| T3–4 | 2 (33.3) | 4 (66.7) | 5 (83.3) | 1 (16.7) | 4 (66.7) | 2 (33.3) | 1 (16.7) | 5 (83.3) | 3 (50.0) | 3 (50.0) | |||||
| N stage | 0.004 | 0.016 | 0.007 | 0.020 | 0.164 | ||||||||||
| N0 | 3 (16.7) | 15 (83.3) | 11 (61.1) | 7 (38.9) | 10 (55.6) | 8 (44.4) | 3 (16.7) | 15 (83.3) | 10 (55.6) | 8 (44.4) | |||||
| N1–2 | 13 (65.0) | 7 (35.0) | 19 (95.0) | 1 (5.0) | 19 (95.0) | 1 (5.0) | 11 (55.0) | 9 (45.0) | 16 (80.0) | 4 (20.0) | |||||
| TNM | 0.088 | 0.034 | 0.052 | 0.039 | 0.296 | ||||||||||
| I | 3 (21.4) | 11 (78.6) | 8 (57.1) | 6 (42.9) | 8 (57.1) | 6 (42.9) | 2 (14.3) | 12 (85.7) | 8 (57.1) | 6 (42.9) | |||||
| II + III | 13 (45.8) | 11 (54.2) | 22 (91.7) | 2 (8.3) | 21 (87.5) | 3 (12.5) | 12 (50.0) | 12 (50.0) | 18 (75.0) | 6 (25.0) | |||||
| Pathology | 0.743 | 1.000 | 1.000 | 1.000 | 0.728 | ||||||||||
| ADC | 7 (40.0) | 12 (60.0) | 15 (78.9) | 4 (21.1) | 14 (73.7) | 5 (26.3) | 7 (36.8) | 12 (63.2) | 12 (63.2) | 7 (36.8) | |||||
| None | 9 (44.4) | 10 (55.6) | 15 (78.9) | 4 (21.1) | 15 (78.9) | 4 (21.1) | 7 (36.8) | 12 (63.2) | 14 (73.7) | 5 (26.3) | |||||
| ADC | |||||||||||||||
Note:
a
P-value was calculated by Fisher’s exact test.
Abbreviations: ADC, adenocarcinoma; CTAs, cancer/testis antigens.